2019 New Treatment Guidelines for Peyronie's Disease

2019 New Treatment Guidelines for Peyronie's Disease:

2019 New Treatment Guidelines for Peyronie's Disease

Urological Associations recommends combining the Penile Traction Devices of Andromedical with Collagenase injections to treat Peyronie.

NEW YORK, November 29, 2018 (Newswire.com) - Andromedical Laboratory has patented and researched Penile Traction Devices for 20 years to develop ANDROPEYRONIE ®, a medical device to treat Peyronie's disease. Based on a clinical study published in The Journal of Sexual Medicine (Nov-2013, Dr. Martínez-Salamanca et al.), ANDROPEYRONIE ® reduces the penile curvature in more than 50 percent, with a pain reduction, an increasing in penile length of 1.5 cm and an improvement in the sexual function. ANDROPEYRONIE ® is the only device registered by the U.S. Food and Drug Administration for PD. More information in: https://www.andropeyronie.com

The new guidelines, presented by the Canadian Urological Association (CUA) in 2018, recommend the use of remodeling technique based on Penile Traction Device of Andromedical (ANDROPEYRONIE®) in combination with collagenase injections to treat patients with Peyronie's disease (PD).